Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

pneumococcal disease

- PMLiVE

Pfizer revenues decline in Q4 but profits surge

Lipitor patent loss continues to hit sales

- PMLiVE

Pfizer launches chronic pain forum

Twitter style comments are used to help patients describe their conditions

- PMLiVE

NICE backs BMS-Pfizer’s Eliquis in atrial fibrillation

Final draft guidance recommends the drug for common heart condition

- PMLiVE

Pfizer gets CHMP backing for leukaemia drug bosutinib

Provides option for patients resistant to tyrosine kinase inhibitors

- PMLiVE

IQWiG finds some value in Pfizer’s Inlyta

Cost effectiveness body decides cancer drug has benefits over Bayer's Nexavar

- PMLiVE

Pfizer enters ADHD market with Quillivant XR launch

Gained rights last November as part of NextWave acquisition

- PMLiVE

Will opportunity knock for eHealth in 2013?

If EC plans succeed, they will transform the way technology is used

- PMLiVE

Pfizer acquires spinal muscular atrophy research programme

Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

FDA clears six new drugs in time for the new year

Brings 2012 tally to 39 – the highest for more than 15 years

- PMLiVE

New EC anti-smoking plans include ban on flavoured tobacco

Pictorial health warnings on cigarettes and regulation for e-cigarettes also proposed

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links